PDF herunterladen
Zeitschrift für Komplementärmedizin 2023; 15(06): 54-60
DOI: 10.1055/a-2188-3635
Praxis
Kognitive Dysfunktion

Kognitive Dysfunktion im Rahmen einer Krebserkrankung und ihrer Behandlung

Matthias Rostock
,
Alena Krause
› Weitere Informationen
    Lizenzen und Reprints

Summary

Die kognitive Dysfunktion hat sich heute zu einer der am häufigsten auftretenden und die Krebspatient*innen oft langfristig am meisten beeinträchtigenden Begleiterscheinungen ihrer Erkrankung entwickelt. Mit den im Rahmen der konventionellen Therapie zur Verfügung stehenden Maßnahmen, insbesondere kognitivem Training, Psychoedukation und körperlicher Aktivität, ergibt sich für viele Patient*innen keine ausreichend zufriedenstellende Besserung. Vor diesem Hintergrund und weil ein großer Anteil der Patient*innen grundsätzlich eine integrative Behandlung ihrer Beschwerden wünscht, werden sehr häufig auch komplementärmedizinische Therapieansätze erfragt.

In dieser Zusammenstellung soll ein Überblick über bereits in ersten klinischen Studien wissenschaftlich untersuchte Therapieverfahren, aber auch über vielversprechende weitere Therapieansätze gegeben werden.

Keywords

Krebs - Krebstherapie - Onkologie - Kognitive Dysfunktion - Phytopharmaka


Publikationsverlauf

Artikel online veröffentlicht:
12. Dezember 2023

© 2023. Thieme. All rights reserved.

© Karl F. Haug Verlag in MVS Medizinverlage Stuttgart GmbH & Co.
KG

 

  • Literatur

  • 1 Wefel JS, Kesler SR, Noll KR. et al Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin 2015; 65 (02) 123-138
    CrossrefPubMedSuche in Google Scholar
  • 2 Fernandes HA, Richard NM, Edelstein K. Cognitive rehabilitation for cancer-related cognitive dysfunction: A systematic review. Support Care Cancer 2019; 27 (09) 3253-3279
    CrossrefPubMedSuche in Google Scholar
  • 3 Hardy SJ, Krull KR, Wefel JS. et al Cognitive changes in cancer survivors. Am Soc Clin Oncol Educ Book 2018; 38: 795-806
    CrossrefPubMedSuche in Google Scholar
  • 4 Cerulla Torrente N, Navarro Pastor JB, de la Osa Chaparro N. Systematic review of cognitive sequelae of non-central nervous system cancer and cancer therapy. J Cancer Surviv 2020; 14 (04) 464-482
    CrossrefPubMedSuche in Google Scholar
  • 5 Lange M, Joly F, Vardy J. et al Cancer-related cognitive impairment: An update on state of the art, detection, and management strategies in cancer survivors. Ann Oncol 2019; 30 (12) 1925-1940
    CrossrefPubMedSuche in Google Scholar
  • 6 Yang M, Kim J, Kim JS. et al Hippocampal dysfunctions in tumor-bearing mice. Brain Behav Immun 2014; 36: 147-155
    CrossrefPubMedSuche in Google Scholar
  • 7 Dietrich J, Han R, Yang Y. et al CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo. J Biol 2006; 05 (07) 22
    CrossrefPubMedSuche in Google Scholar
  • 8 Wefel JS, Schagen SB. Chemotherapy-related cognitive dysfunction. Curr Neurol Neurosci Rep 2012; 12 (03) 267-275
    CrossrefPubMedSuche in Google Scholar
  • 9 Briones TL, Woods J. Dysregulation in myelination mediated by persistent neuroinflammation: Possible mechanisms in chemotherapy-related cognitive impairment. Brain Behav Immun 2014; 35: 23-32
    CrossrefPubMedSuche in Google Scholar
  • 10 Wefel JS, Ryan CJ, Van J. et al Assessment and management of cognitive function in patients with prostate cancer treated with second-generation androgen receptor pathway inihibitors. CNS Drugs 36 (05) 419-449
    CrossrefPubMed
  • 11 Zwart W, Terra H, Linn SC. et al Cognitive effects of endocrine therapy for breast cancer: Keep calm and carry on?. Nat Rev Clin Oncol 2015; 12 (10) 597-606
    CrossrefPubMedSuche in Google Scholar
  • 12 Hermelink K, Bühner M, Sckopke P. et al Chemotherapy and post-traumatic stress in the causation of cognitive dysfunction in breast cancer patients. J Natl Cancer Inst 2017; 109: 10
    CrossrefPubMedSuche in Google Scholar
  • 13 Schilling G. Das sogenannte „Chemobrain“ – Kognitive Dysfunktion bei Krebskranken – ein oft unterbewertetes Symptom. Im Fokus Onkologie 2023; 26 (04) 52-56
    CrossrefSuche in Google Scholar
  • 14 Deutsche Krebshilfe, Deutsche Krebsgesellschaft AWMF. S3-Leitlinie Komplementärmedizin in der Behandlung von onkologischen PatientInnen (09/2021). Im Internet. www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin Stand: 06.11.2023
  • 15 Derry HM, Jaremka LM, Bennett JM. et al Yoga and self-reported cognitive problems in breast cancer survivors: A randomized controlled trial. Psychooncology 2015; 24 (08) 958-966
    CrossrefPubMedSuche in Google Scholar
  • 16 Janelsins MC, Peppone LJ, Heckler CE. et al YOCAS©® yoga reduces self-reported memory difficulty in cancer survivors in a nationwide randomized clinical trial: Investigating relationships between memory and sleep. Integr Cancer Ther 2016; 15 (03) 263-271
    CrossrefPubMedSuche in Google Scholar
  • 17 Cramer H, Lauche R, Klose P. et al Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer. Cochrane Database Syst Rev 2017; 01 (01) CD010802
    CrossrefPubMedSuche in Google Scholar
  • 18 Johns SA, Brown LF, Beck-Coon K. et al Randomized controlled pilot trial of mindfulness-based stress reduction compared to psychoeducational support for persistently fatigued breast and colorectal cancer survivors. Support Care Cancer 2016; 24 (10) 4085-4096
    CrossrefPubMedSuche in Google Scholar
  • 19 Tong T, Pei C, Chen J. et al Efficacy of acupuncture therapy for chemotherapy-related cognitive impairment in breast cancer patients. Med Sci Monit 2018; 24: 2919-2927
    CrossrefPubMedSuche in Google Scholar
  • 20 Seo EJ, Klauck SM, Efferth T. et al Adaptogens in chemobrain (Part I): Plant extracts attenuate cancer chemotherapy-induced cognitive impairment – Transcriptome-wide microarray profiles of neuroglia cells. Phytomedicine 2019; 55: 80-91
    CrossrefSuche in Google Scholar
  • 21 Abulizi A, Ran J, Ye Y. et al Ganoderic acid improves 5-fluorouracil-induced cognitive dysfunction in mice. Food Funct 2021; 12 (24) 12325-12337
    CrossrefPubMedSuche in Google Scholar
  • 22 Sadeghian M, Rahmani S, Zendehdel M. et al Ginseng and cancer-related fatigue: A systematic review of clinical trials. Nutr Cancer 2021; 73 (08) 1270-1281
    CrossrefPubMedSuche in Google Scholar
  • 23 Darbinyan V, Aslanyan G, Amroyan E et a. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry 2007; 61 (05) 343-348
    CrossrefPubMedSuche in Google Scholar
  • 24 Ishaque S, Shamseer L, Bukutu C. et al Rhodiola rosea for physical and mental fatigue: A systematic review. BMC Complement Altern Med 2012; 12: 70
    CrossrefPubMedSuche in Google Scholar
  • 25 Barton DL, Atherton PJ, Bauer BA. et al The use of valeriana officinalis (valerian) in improving sleep in patients who are undergoing treatment for cancer: A phase III randomized, placebo-controlled, double-blind study (NCCTG Trial, N01C5). J Support Oncol 2011; 09 (01) 24-31
    CrossrefPubMedSuche in Google Scholar
  • 26 Zick SM, Sen A, Wyatt GK. et al Investigation of 2 types of self-administered acupressure for persistent cancer-related fatigue in breast cancer survivors: A randomized clinical trial. JAMA Oncol 2016; 02 (11) 1470-1476
    CrossrefPubMedSuche in Google Scholar
  • 27 Speers AB, Cabey KA, Soumyanath A. et al Effects of withania somnifera (ashwagandha) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Curr Neuropharmacol 2021; 19 (09) 1468-1495
    CrossrefPubMedSuche in Google Scholar
  • 28 Biswal BM, Sulaiman SA, Ismail HC. et al Effect of withania somnifera (ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integr Cancer Ther 2013; 12 (04) 312-322
    CrossrefPubMedSuche in Google Scholar
  • 29 Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev 2008; 2008 (04) CD000448
    CrossrefPubMedSuche in Google Scholar
  • 30 European Medicines Agency. European Union herbal monograph on Ginkgo biloba L., folium EMA/HMPC/2012; (28.01.2015). Im Internet. https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-ginkgo-biloba-l-folium_en.pdf Stand: 06.11.2023
  • 31 Attia A, Rapp SR, Case LD. et al Phase II study of Ginkgo biloba in irradiated brain tumor patients: Effect on cognitive function, quality of life, and mood. J Neurooncol 2012; 109 (02) 357-363
    CrossrefPubMedSuche in Google Scholar
  • 32 Barton DL, Burger K, Novotny PJ. et al The use of ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9. Support Care Cancer 2013; 21 (04) 1185-1192
    CrossrefPubMedSuche in Google Scholar
  • 33 Pelzer F, Loef M, Martin DD. et al Cancer-related fatigue in patients treated with mistletoe extracts: A systematic review and meta-analysis. Support Care Cancer 2022; 30 (08) 6405-6418
    CrossrefPubMedSuche in Google Scholar
  • 34 Dominguez LJ, Barbagallo M. Nutritional prevention of cognitive decline and dementia. Acta Biomed 2018; 89 (02) 276-290
    CrossrefPubMedSuche in Google Scholar
  • 35 Fried TR, Bradley EH, Towle VR. et al Understanding the treatment preferences of seriously ill patients. N Engl J Med 2002; 346 (14) 1061-1066
    CrossrefPubMedSuche in Google Scholar